Conference
Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up
Authors
Lipton JH; Hughes TP; Leber B; De Souza C; Dorlhiac-Llacer PE; Steegmann JL; Guerci-Bresler A; Schwarer AP; Cervantes F; Reynolds J
Volume
30
Publisher
AMER SOC CLINICAL ONCOLOGY
Publication Date
May 20, 2012
Name of conference
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference place
Chicago, IL
Conference start date
June 1, 2012
Conference end date
June 6, 2012
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
15
ISSN
0732-183X